A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutationSubotheni Thavaneswaran, David M. Thomas, Michael D. Brown et al.|npj Precision Oncology|2024Cited by 6
Trastuzumab emtansine (T-DM1) in advanced cancers with <i>HER2 </i>mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.Subotheni Thavaneswaran, David M. Thomas, Antony Mersiades et al.|Journal of Clinical Oncology|2023Cited by 2
Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.Frank Lin, David M. Thomas, Subotheni Thavaneswaran et al.|Journal of Clinical Oncology|2023Cited by 2
636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudyBenjamin Y. Kong, David Goldstein, Frank Lin et al.|Annals of Oncology|2024Cited by 0
Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) FrameworkDanielle Blunt, Steven Lane, Rosemary Harrup et al.|Blood|2024Cited by 0